A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.
暂无分享，去创建一个
M. Gore | B. Melichar | V. Matveev | J. Bellmunt | B. Alekseev | S. Bracarda | R. V. van Moorselaar | M. Staehler | E. Fernebro | R. Jančiauskienė | P. Mulders | S. Osborne | S. Ivanov | A. Zyryanov | S. Jethwa | G. Mickisch | N. Magné | V. Matveev | N. Magné | Joaquim Bellmunt | P. Mulders | R. V. Moorselaar